28 June, 2017

We are very pleased to announce a renewed commitment to MS Research Australia of $825,000 from the Commonwealth […]

25 May, 2017

An exciting large-scale phase 3 trial is about to begin in the UK. The trial is investigating whether […]

02 May, 2017

The Australian government has announced that Zinbryta (daclizumab) is now available on the Pharmaceutical Benefits Scheme (PBS) for […]

27 April, 2017

The American Academy of Neurology is currently meeting in Boston. Scientific meetings like this are vital for the […]

22 April, 2017

The last decade has seen the development of a number of new treatments for relapsing forms of MS. […]

21 April, 2017

Advances in medicine and medical technology relies on the successful translation of fundamental laboratory research to clinical implementation. […]

31 March, 2017

Often scientific advancements are considered to occur behind the closed doors of high-tech laboratories, staffed by scientists in […]

30 March, 2017

The American Food and Drug Administration (FDA) has approved OCREVUS™ (ocrelizumab) for the treatment of both relapsing and […]

10 January, 2017

The full clinical trial results have been published for ocrelizumab (Ocrevus®), a new treatment option for primary progressive […]

07 December, 2016

There is a lot of interest in the MS community in the potential treatment option for MS known […]

Contact Us

We're not around right now. But you can send us an email and we'll get back to you, asap.

Start typing and press Enter to search